Search results for " progress"

showing 10 items of 1287 documents

Cognitive processess and cognitive reserve in multiple sclerosis

2015

Multiple Sclerosis (MS) is characterized by motor, cognitive, and neuropsychiatric symptoms, which can occur independently. While MS is traditionally considered an inflammatory disease of the white matter, degeneration of gray matter is increasingly recognized as an important contributor to the progressive cognitive decline. A protective factor against the progression of cognitive dysfunction in MS could be the cognitive reserve, defined as resistance to brain dysfunction. Aim of the present study is to evaluate the role of cognitive reserve for different aspects of cognitive dysfunction of patients with MS. We found that patients with MS and lower cognitive reserve have poorer neuropsychol…

AdultMaleMultiple SclerosisSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaPhysiologyMultiple sclerosis • Cognitive Reserve • Verbal cognitive processes • Visual-space processesCell BiologyGeneral MedicineMiddle AgedNeuropsychological TestsCognitionCognitive ReserveDisease ProgressionHumansFemalePsychomotor Performance
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct

Reducing Body Myopathy with Cytoplasmic Bodies and Rigid Spine Syndrome: A Mixed Congenital Myopathy

2001

At the age of five years a male child started to develop a progressive rigid spine, torsion scoliosis, and flexion contractures of his elbows, knees, hips, and ankles owing to severe proximal and distal muscle weakness. He had three muscle biopsies from three different muscles at ages 7, 11, and 14 years, respectively. Myopathologically, these muscle tissues contained numerous inclusions which, at the ultrastructural level, turned out to be reducing bodies and cytoplasmic bodies, often in close spatial proximity. Similar histological inclusions, although not further identified by histochemistry and electron microscopy, were seen in his maternal grandmother's biopsied muscle tissue who had d…

AdultMaleMuscle tissuePathologymedicine.medical_specialtyWeaknessScoliosisSpinal Muscular Atrophies of ChildhoodSarcomereMyositis Inclusion BodymedicineHumansGenetic Predisposition to DiseaseMuscle SkeletalMyopathyMyositisAgedInclusion Bodiesbusiness.industrySyndromeGeneral MedicineAnatomymedicine.diseasePenetrancePedigreemedicine.anatomical_structureChild PreschoolPediatrics Perinatology and Child HealthDisease ProgressionLordosisFemaleDesminNeurology (clinical)medicine.symptombusinessMyopathies Structural CongenitalNeuropediatrics
researchProduct

Extremely High Mutation Rate of HIV-1 In Vivo.

2015

Rates of spontaneous mutation critically determine the genetic diversity and evolution of RNA viruses. Although these rates have been characterized in vitro and in cell culture models, they have seldom been determined in vivo for human viruses. Here, we use the intrapatient frequency of premature stop codons to quantify the HIV-1 genome-wide rate of spontaneous mutation in DNA sequences from peripheral blood mononuclear cells. This reveals an extremely high mutation rate of (4.1 ± 1.7) × 10−3 per base per cell, the highest reported for any biological entity. Sequencing of plasma-derived sequences yielded a mutation frequency 44 times lower, indicating that a large fraction of viral genomes …

AdultMaleMutation rateSequence analysisQH301-705.5Nonsense mutationHIV InfectionsBiologyGeneral Biochemistry Genetics and Molecular BiologyYoung AdultMutation RateHumansMutation frequencyBiology (General)GeneticsGeneral Immunology and MicrobiologySequence Analysis RNAGeneral NeuroscienceMiddle AgedVirologyReverse transcriptaseStop codon3. Good healthMutation (genetic algorithm)Disease ProgressionSynopsisHIV-1FemaleGeneral Agricultural and Biological SciencesViral loadResearch ArticlePLoS Biology
researchProduct

Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis

2011

We tested for the presence of coronary calcifications in patients with chronic renal disease not on dialysis and studied its progression in 181 consecutive non-dialyzed patients who were followed for a median of 745 days. Coronary calcifications (calcium score) were tallied in Agatston units by computed tomography, and the patients were stratified into two groups by their baseline calcium score (100 U or less and over 100 U). Survival was measured by baseline calcium score and its progression. Cardiac death and myocardial infarction occurred in 29 patients and were significantly more frequent in those patients with calcium scores over 100 U (hazard ratio of 4.11). With a calcium score of 10…

AdultMaleNephrologymedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentMyocardial Infarctioncardiovascular events chronic kidney disease coronary calcificationCoronary Artery DiseaseKaplan-Meier EstimateCohort StudiesCoronary artery diseasecardiovascular eventsRisk FactorsCalcinosisInternal medicinemedicineHumansMyocardial infarctionRenal Insufficiency ChronicDialysisAgedSettore MED/14 - Nefrologiabusiness.industryHazard ratiocoronary calcificationCalcinosisMiddle AgedPrognosismedicine.diseasecardiovascular eventSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryNephrologyDisease ProgressionCardiologyFemaleOriginal Articlebusinesschronic kidney diseaseKidney diseaseCalcification
researchProduct

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

2018

Background Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development of stage ≥3 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of stage ≥3 CKD in a large cohort of patients affected by T1DM. Methods A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the Italian Association of Clinical Diabetologists (Associazione Medici D…

AdultMaleNephrologymedicine.medical_specialtyendocrine system diseasesRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologylcsh:RC870-923Kidneyurologic and male genital diseasesGFR03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusmedicineHumansAlbuminuriaDiabetic kidney diseaseKidneyType 1 diabetesurogenital systembusiness.industryIncidence (epidemiology)Middle Agedlcsh:Diseases of the genitourinary system. Urologymedicine.diseasefemale genital diseases and pregnancy complicationsAlbuminuria Diabetic kidney disease GFR NephrologyDiabetes Mellitus Type 1medicine.anatomical_structureItalyNephrologyDisease ProgressionAlbuminuriaFemalemedicine.symptombusinessResearch ArticleFollow-Up StudiesGlomerular Filtration RateKidney disease
researchProduct

Factors affecting recurrence and progression in superficial bladder tumours

1995

Prognostic factors in superficial bladder tumours are highly correlated with each other. In this study, their relative importance is examined and grouping of patients in three different prognostic groups suggested. 576 patients (from EORTC protocols 30790 and 30782) were analysed. They have been followed from 3 months to 8.6 years with a median of 4 years. 76 patients developed an invasive tumour (or = T2); the shortest time to invasion was 12 weeks, the longest was 6.6 years. Time from invasion to death ranged from 3 weeks to 4.4 years with a median of 2 years. Prognostic factors contributing to recurrence, invasion and survival were investigated: age, sex, size of largest tumour, number o…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyTime FactorsMultivariate analysisAdolescentMalignant diseaseRisk groupsRisk FactorsInternal medicinemedicineCarcinomaHumansNeoplasm InvasivenessIn patientSurvival rateAgedAged 80 and overAnalysis of VarianceCarcinoma Transitional Cellbusiness.industryMiddle AgedPrognosismedicine.diseaseSurgerySurvival RateTransitional cell carcinomaUrinary Bladder NeoplasmsOncologyTumour sizeDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean Journal of Cancer
researchProduct

Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease

2014

Chronic obstructive pulmonary disease (COPD) and lung cancer are widespread lung diseases. Cigarette smoking is a high risk factor for both the diseases. COPD may increase the risk of developing lung cancer. Thus, it is crucial to be able to distinguish between these two pathological states, especially considering the early stages of lung cancer. Novel diagnostic and monitoring tools are required to properly determine lung cancer progression because this information directly impacts the type of the treatment prescribed. In this study, serum samples collected from 22 COPD and 77 lung cancer (TNM stages I, II, III, and IV) patients were analyzed. Then, a collection of NMR metabolic fingerprin…

AdultMaleOncologymedicine.medical_specialtyLung NeoplasmsMagnetic Resonance SpectroscopyClinical BiochemistryPharmaceutical ScienceCreatineAnalytical ChemistryDiagnosis DifferentialPulmonary Disease Chronic Obstructivechemistry.chemical_compoundPredictive Value of TestsCarcinoma Non-Small-Cell LungInternal medicineDrug DiscoveryBiomarkers TumormedicineHumansMetabolomicsLeast-Squares AnalysisRisk factorLung cancerLungPathologicalEarly Detection of CancerSpectroscopyAgedNeoplasm StagingAged 80 and overUnivariate analysisCOPDLungChemistryDiscriminant AnalysisMiddle AgedPrognosismedicine.diseaserespiratory tract diseasesmedicine.anatomical_structureMultivariate AnalysisDisease ProgressionFemaleLung cancer stagingJournal of Pharmaceutical and Biomedical Analysis
researchProduct

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study

2021

Background: Easily accessible biomarkers enabling the identification of those patients with multiple sclerosis (MS) who will accumulate irreversible disability in the long term are essential to guide early therapeutic decisions. We here examine the utility of serum neurofilament light chain (sNfL) for forecasting relapse-free disability progression and conversion to secondary progressive MS (SPMS) in the prospective Neurofilament and longterm outcome in MS (NaloMS) cohort. Methods: The predictive ability of sNfL at Baseline and sNfL follow-up (FU)/ Baseline (BL) ratio with regard to disability progression was assessed within a development cohort (NaloMS, n=196 patients with relapsing-remitt…

AdultMaleOncologymedicine.medical_specialtyMedicine (General)Logistic regressionGeneral Biochemistry Genetics and Molecular BiologyMultiple sclerosisYoung AdultMultiple Sclerosis Relapsing-RemittingR5-920Neurofilament ProteinsInterquartile rangeInternal medicinemedicineHumansLongitudinal StudiesProspective StudiesRisk factorNeurofilament light chainSPMS transitionDisease progressionClinically isolated syndromebusiness.industryRGeneral MedicineOdds ratioMultiple Sclerosis Chronic ProgressiveConfidence intervalCohortMedicineFemalebusinessBiomarkersResearch PaperCohort studyEBioMedicine
researchProduct

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective ana…

2014

Abstract Background Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS). ABC -transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1 - and ABCG2 -genes. Results 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no associa…

AdultMaleOncologymedicine.medical_specialtyTreatment responseATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentImmunologyPrimary Progressive Multiple SclerosisPharmacologyInternal medicineGenotypeLack of efficacymedicineRetrospective analysisATP Binding Cassette Transporter Subfamily G Member 2HumansImmunology and AllergyRetrospective StudiesAnalgesicsMitoxantronebusiness.industryImmunosuppressionMiddle AgedMultiple Sclerosis Chronic ProgressiveNeoplasm Proteins3. Good healthNeurologyPharmacogeneticsATP-Binding Cassette TransportersFemaleNeurology (clinical)MitoxantronebusinessPharmacogeneticsmedicine.drugJournal of Neuroimmunology
researchProduct